GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » LT-Debt-to-Total-Asset

Affymax, (FRA:A5Y) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Affymax, LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Affymax,'s long-term debt to total assests ratio for the quarter that ended in Jun. 2014 was 0.00.

Affymax,'s long-term debt to total assets ratio stayed the same from Jun. 2013 (0.00) to Jun. 2014 (0.00).


Affymax, LT-Debt-to-Total-Asset Historical Data

The historical data trend for Affymax,'s LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, LT-Debt-to-Total-Asset Chart

Affymax, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Affymax, Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Affymax, LT-Debt-to-Total-Asset Calculation

Affymax,'s Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2013 is calculated as

LT Debt to Total Assets (A: Dec. 2013 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2013 )/Total Assets (A: Dec. 2013 )
=0/5.433
=0.00

Affymax,'s Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2014 is calculated as

LT Debt to Total Assets (Q: Jun. 2014 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2014 )/Total Assets (Q: Jun. 2014 )
=0/3.963
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affymax,  (FRA:A5Y) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Affymax, LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Affymax,'s LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax, (FRA:A5Y) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines